Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 29;14:7825. doi: 10.1038/s41467-023-43381-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a. Kaplan-Meier plots of progression free survival in 253 atezo/bev-treated (top) versus 58 sorafenib-treated advanced HCC patients (bottom) with high versus low (split by median) CD8 T_EMRA (left) or Macro CXCL10 (right) enrichment score, calculated per sample in bulk RNA-sequencing data. P-values calculated using the log-rank test. Median progression free survival as indicated. b. Scatter plot depicting the correlation between CD8 T_EMRA and Macro CXCL10 enrichment scores, calculated per sample in bulk RNA-sequencing data of 311 advanced HCC patients. P values calculated using two-sided Spearman’s rank correlation test. R-values are Spearman’s rank correlation coefficients (rho). Error bands represent the 95% confidence interval. c. Kaplan-Meier plots of overall survival (left) and progression free survival (right) in 253 atezo/bev-treated (top) versus 58 sorafenib-treated advanced HCC patients (bottom) with high versus low atezo/bev-response biomarker enrichment score (using optimal cut-off determined by maximally selected rank statistics, see Methods for details), calculated per sample in bulk RNA-sequencing data. (Atezo/bev, atezolizumab plus bevacizumab; PFS, Progression free survival).